peopleInnovationCareers RarePipelineCollaborationFinanceAdvance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma

Hansa Medical’s annual report of 2012 (in Swedish) has been published

15 Apr 2013, 14:00
Regulatory information
The Hansa Medical Annual Report of 2012 (in Swedish) has been published at the corporate website www.hansamedical.com

A print version of the annual report in Swedish can be ordered at Hansa Medical AB, Investor Relations, P.O. Box 785, 220 07 Lund, Sweden, via fax +46 46 12 77 75 or via e-mail at info@hansamedical.com

For further information, please contact:
Hansa Medical AB
Emanuel Björne, CEO
Mobile: 46 707 17 54 77
E-mail: emanuel.bjorne@hansamedical.com

Hansa Medical pursues clinical development and commercialization of innovative pharmaceuticals and diagnostic methods for the benefit of patients with serious and rare inflammatory diseases. The portfolio includes a marketed diagnostic product, a drug candidate in Phase I trial, and a preclinical research project. Major shareholders are Bo Håkansson via Farstorps Gård AB, and Bengt Ågerup via Nexttobe AB. Hansa Medical is listed on NASDAQ OMX First North (HMED) and Remium Nordic AB is the company’s Certified Adviser.